Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non–Small Cell Lung Cancer Based on Mutational Status

Overview of attention for article published in American Journal of Clinical Oncology: Cancer Clinical Trials, October 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 41 Mendeley

Summary X

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 18,895 followers.

@ShakeKumarMD @doximity Here is ours https://t.co/TVcDkBuFko

30 Jun 2020

Reply Repost Favourite

Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status. #lymphoma #lymsm https://t.co/XtS7mNoSuV

25 Mar 2020

Reply Repost Favourite

Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status. https://t.co/XxgBDeHlIv H/T @NCBI #radonc #PubMed

25 Mar 2020

Reply Repost Favourite

RT @PittGIM: Adding stereotactic body radiation therapy (SBRT) to maintenance therapy is not a cost-effective strategy for oligometastatic…

01 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.